Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylhydrazine is a small organic compound (C6H5NHNH2) that was the first hydrazine derivative characterized. It acts as a chemical intermediate primarily in the synthesis of dyes, pharmaceuticals, and pesticides[3][1][4][5]. It is also used in analytical chemistry for the identification and separation of sugars via phenylhydrazone formation and in the Fischer indole synthesis to prepare indoles for medicinal chemistry[3][1]. Historically, phenylhydrazine and its hydrochloride were used medicinally to treat blood disorders such as polycythemia but are now rarely employed due to toxicity concerns[7]. As a hydrazine derivative, its mechanism involves the reduction of diazonium salts and reactivity with aldehydes/ketones to form hydrazones; it also induces hemolytic anemia in animal models by binding to hemoglobin, leading to red blood cell destruction[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylhydrazine.